ATRA ATARA BIOTHERAPEUTICS INC Operational Disruptions 8-K Filing 2023 - Announcement of Phase 2 EMBOLD Study Results Atara Biotherapeutics announces top-line results from Phase 2 EMBOLD study of ATA188 for non-active progressive multiple sclerosis.Get access to all SEC 8-K filings of the ATARA BIOTHERAPEUTICS INC